An update from Roquefort Investments PLC ( (GB:ROQ) ) is now available.
Roquefort Therapeutics PLC has announced significant board changes as part of a planned transition. CEO Ajan Reginald and Non-Executive Director Prof. Sir Martin Evans will resign, with Dr. Darrin M Disley OBE stepping in as Interim Managing Director. This transition aligns with the company’s strategy to complete the trade sales of its subsidiaries, Lyramid Pty Ltd and Oncogeni Limited, marking a pivotal moment in its business strategy execution. The leadership change is expected to bolster the company’s future strategy and operations, with Dr. Disley’s extensive experience in life sciences anticipated to drive further growth and value creation.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the London Stock Exchange, focusing on developing first-in-class drugs in the high-value and high-growth immunology and oncology markets. The company’s portfolio includes five novel patent-protected pre-clinical anti-cancer and immunology assets.
YTD Price Performance: -61.73%
Average Trading Volume: 1,417,075
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.1M
See more data about ROQ stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com